Parixol 88mcg Tablet 10pcs

Uses of Parixol 88mcg Tablet

Parkinson's disease, Restless leg syndrome

How does Parixol 88mcg Tablet work?

Parixol 88mcg Tablet works by increasing the action of dopamine, a chemical messenger that is needed to control movement in the brain.

Side Effects of Parixol 88mcg Tablet

• Dizziness
• Sleepiness
• Nausea
• Dryness in mouth
• Fatigue
• Hallucination
• Constipation
• Peripheral edema

Quick Suggestions:

• Take as prescribed for Parkinson's disease and/or restless leg syndrome.
• Can be taken with or without food (taking it with food may reduce nausea).
• For restless leg syndrome, take 2 to 3 hours before bedtime.
• Avoid activities requiring alertness (e.g., driving) until the medication's effects are known.
• Be cautious of sudden blood pressure drops when changing positions.
• Rise slowly from sitting or lying down to prevent dizziness.
• Report hallucinations or behavioral changes to the doctor promptly.
• Inform the doctor about any compulsive behaviors like binge eating, gambling, spending, or sexual urges.
• Do not stop the medication suddenly; consult with the doctor before any discontinuation.
• Keep the doctor informed about any developments or concerns during treatment.

Indication of Parixol 88mcg Tablet

Parkinson's Disease:

• Treatment of Parkinson's disease, whether used independently or as an adjunct alongside levodopa with a dopa decarboxylase inhibitor.
• Pramipexole, a nonergot-derivative dopamine receptor agonist, steps up to the challenge of alleviating motor impairments in Parkinson's, enhancing postsynaptic dopamine activity in the striatum and substantia nigra.

2. Restless Legs Syndrome:

• Addressing the spectrum from moderate to severe restless legs syndrome, Pramipexole emerges as a therapeutically.
• The prowess of Pramipexole extends beyond Parkinson's, standing resilient against the challenges posed by restless legs syndrome.

Pharmacology

• Pramipexole, the non-ergot-derivative dopamine receptor agonist, takes center stage in the pharmacological arena.
• Its direct augmentation of postsynaptic dopamine activity in the striatum and substantia nigra unlocks relief, specifically tailored for alleviating the motor impairments that Parkinson's unfurls.
• In the intricate dance of neurotransmitters, Pramipexole proves its mettle, serving as an adjuvant to levodopa for symptomatic therapy in advanced Parkinsonian syndrome.
• Not confined to a supporting role, Pramipexole also shines as a monotherapy, offering solace to those grappling with the early symptoms of Parkinsonian syndrome.

Dosage & Administration of Parixol 88mcg Tablet

Parkinson's Disease:

Initiate with Precision:

• Initial Dose: Commence with 88 micrograms three times daily.
• Gradual Upward Adjustment: Double the dose every 5-7 days if well-tolerated, reaching up to 350 micrograms three times daily.
• Further Fine-Tuning: If necessary, continue the upward titration with increments of 180 micrograms three times daily at weekly intervals.
• Caution on Maximum Front: Exercise prudence, capping the daily dose at 3.3 mg, strategically divided into three doses.
• Harmony with Levodopa: During the delicate orchestration of pramipexole dose titration and maintenance, orchestrate a reduction in levodopa dosage for synchronized efficacy.

Restless Legs Syndrome: 

Initiate with Delicacy:

• Initial Dose: Embark with 88 micrograms once daily, precisely administered 2-3 hours before bedtime.
• Stepwise Ascendancy: Double the dose at intervals of 4-7 days if the need arises, reaching a maximum of 350 micrograms daily.

Maximum Threshold:

• Capping the Relief: Exercise prudence, confining the maximum daily dose to 540 micrograms.

Interaction

• Unique Metabolism: Pramipexole stands out as a dopamine agonist due to its distinctive characteristic of not undergoing substantial metabolization by the P450 system.
• Reduced Drug-Drug Interaction Risk: This metabolic trait significantly diminishes the risk of drug-drug interactions compared to other dopamine agonists that are extensively metabolized by the P450 system.
• Renal Clearance Impact: Cimetidine and amantadine may influence pramipexole renal clearance. Prescribers should be mindful of potential interactions when these medications are co-administered.
• Sedating Substances Warning: Caution is advised when combining pramipexole with sedating medications or alcohol. The potential for cumulative effects should be acknowledged to prevent adverse outcomes.

Contraindications

Patients with known hypersensitivity to the active ingredient or any of the excipients should avoid pramipexole.

Pregnancy & Lactation

Because the effect of pramipexole on pregnancy and breastfeeding in humans has not been studied, it should only be taken during pregnancy if the possible benefit outweighs the risk to the fetus. In humans, pramipexole suppresses prolactin secretion. Because pramipexole's excretion into breast milk has not been investigated in women, it should not be used while they are breastfeeding. Breast-feeding, on the other hand, should be stopped if it is unavoidable.

Precaution & Warnings:

Handle with Caution:

• Psychotic Disorder Alert: Pramipexole is contraindicated in individuals with psychotic disorders due to the risk of symptom exacerbation and earlier onset.
• Cardiovascular Caution: Exercise prudence in severe cardiovascular disease cases.
• Augmentation Awareness: Vigilance is crucial for identifying any augmentation, characterized by an earlier onset, increase, and spread of symptoms.
• Neuroleptic Malignant Syndrome Risk: Abrupt withdrawal poses a risk of neuroleptic malignant syndrome. To mitigate, initiate a careful tapering regimen at 750 mcg/day for a week, followed by a subsequent reduction of 375 mcg/day.
• Renal Prudence: Exercise caution in individuals with renal impairment.
• Pregnancy and Lactation Advisory: Pramipexole usage in pregnancy and lactation requires careful consideration and consultation with healthcare providers.

Patient Counseling:

• Alertness Advisory: Advise patients to abstain from activities demanding mental alertness and physical coordination post-drug intake.

Monitoring Parameters:

• Blood Pressure Surveillance: Regular monitoring of blood pressure is essential.
• Fibrosis and Orthostatic Hypotension Vigilance: Keep a watchful eye for signs and symptoms of fibrosis and orthostatic hypotension.
• Impulse Control Disorder Watch: Be vigilant for the development of impulse control disorders and behavioral changes.
• Skin Examination Routine: Periodic skin examinations are recommended.
• Ophthalmological Oversight: Due to the risk of visual disorders, regular ophthalmological testing is crucial.

Storage Conditions

Store in a cool and dry place. Protect from light.